Special Issue

Harnessing Cancer Vulnerability by Targeting the DNA Damage Response

Message from the Guest Editor

In the precision medicine era, while agents that suppress oncogenic kinases have changed the standard of care for many cancers, no effective therapies are available for tumours, such as breast and ovarian cancer (OC), which are lacking in actionable driver cancer mutations. Luckily, the genome instability induced by the high frequency of DNA damage repair (DDR) defects has opened new avenues and treatment perspectives for such tumours.

My main interest in launching this Special Issue is to focus the discussion on innovative data in order to support clinical strategies for extending the advantages of PARP inhibitors beyond BRCA mutant cancers and towards a wider number of patients, through the use of novel biomarkers of homologous recombination repair deficiency as well as of predictive biomarkers of sensitivity. I would like to attract research and/or review articles to explore the potential application of PARP inhibitors in early treatment schemes, including neoadjuvant, adjuvant, and chemo/radio-prevention approaches.

Guest Editor

Dr. Angela Celetti

Departement of Biomedical Science, Institute for Experimental Oncology and Endocrinology, National Research Council (CNR, ITALY), Via Pansini, 5, 80131, Naples, Italy

Deadline for manuscript submissions

closed (30 April 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/64443

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)